Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There is a good movie on Netflix called Dumb Money, which dramatizes the whole Roaring Kitty story and the GameStop squeeze. It demonstrates very well the corruption of the market by short hedge funds and brokerages.
Be prepared for a SHORT SQUEEZE on AVXL stock!!!
Good luck and GOD bless,
Does "Roaring Kitty," who was identified as Keith Gill on Reddit know about Anavex AVXL?
Good luck and GOD bless,
P.S. I believe it was reported that the mabs' brain volume loss was greater than those AD patients without treatment and/or those on the placebos.
Here is what was reported by each company:
-12.93/-4.9 = 2.64
Sorry, Ziggy, I was a little too high in my rounding.
William, not to mention that some of the shorts in AVXL are getting margin calls on their GME short positions. A liquidity issue.
You were still wrong regardless.
Expect well over 1 million shares of AVXL to be purchased today!!!
Good luck and GOD bless,
Yes, that is true, but if the lawyers state, "Don't release," almost all CEO''s will not release. Too much personal liability if s/he were wrong.
The difference between the analogy you are asserting is that Agency decision making processes are much more opaque than judicial processes.
Court Rules must favor indefinite action similar to this last.
The distraction(s) may see NO END until more definitive results
from AVXL either assure its relevance or make make them moot.
I was hoping to grab 20% on "interest" through $5.
May have to settle for less FOMO.
GME spillover is a good narrative for bashers. I like my own narrative, "A good 1st quarter report three trading days ago finally sunk in and raised share price." I have observed that News seems to pull a "sticky price" with a rubber band. It resists for three days and then snaps up. But I am hardly an old hand, any other opinions would be appreciated.
It seems a stay at a Holiday Inn is all that is necessary
to determine a proper resolution to some situations.
That said, I trust awaiting three weeks for $4 was the correct strategy.
Still consider tight stops to be appropriate and any LONG TERM gains
still a ways off.
Yes, Ignatius, I believe that GME has added about $3-$4 billion in market cap this AM. I think that AVXL and other Biotechs are getting some positive spillover effect.
As you might understand the whole point of the class action system is to consolidate plaintiffs complaints into one for all similarly situated.
Hopefully you are not surprised by the two complaints being similar.
If the case is weak or is for the court to decide, just like whether Anavex trial results are weak or strong enough for approval is for the appropriate regulatory authorities to decide.
The new complaint is effectively the same case as the prior complaint, and is just as weak.
No it's the CEOs decision.
"That's what you get for overexcited placebo scores! No silver for you. Bah."
Unfortunately an other class action was filed 8th May, so now the judge can't dismiss the case at least just yet: https://www.courtlistener.com/docket/68511120/downing-v-anavex-life-sciences-corporation/
This case is now referred to Judge Colleen McMahon as possibly related to 1:24-cv-01910-CM. So we now wait longer to find out what the Judge decides next and which if any of the two plaintiffs might be appointed lead plaintiff.
Exactly... when your daughter doesn't experience the side-effect of GI issues, as with trofinetide, then you can be fairly sure your daughter is on a placebo... so don't expect to see any improvement. That situation didn't exist with the safety of blarcamesine, without side-effects... therefore, parents were hopeful their daughters were on the actual drug, when actually they weren't, so evaluations were skewed higher. Pretty simple, really.
Why only bronze sponsor given how well WGT believe things are going for Anavex - bit cheap skate that.
Thank you to Anovo, @AnavexLifeSci, and DepYmed, the bronze sponsors of this year's ASCEND 2024 Rett Syndrome National Summit! Time is running out to register - reserve your spot today at https://t.co/b5o6vPkyKl. pic.twitter.com/Cpi948SIF3
— International Rett Syndrome Foundation (@Rettsyndrome) May 13, 2024
The fact is that the competition’s placebo effect was more than 3 times worse than the powerful Anavex induced placebo response.
Rett results are not accurate. The placebo effect means they were not actually 3x better than the competition. It means they were just as great without the drug at all...
Plus, I don't think Rett results were 3X better than competition.
mrp, the lawyers are the decision makers on when information/data needs to be released to shareholders. As of today, they have not made that decision to release.
PW don't deflect...WHERE IS THE DATA? IT IS AVAILABLE, IT IS MATERIAL AND THE LACK OF RELEASE IS CAUSING HARM TO SHARHOLDERS.
I COME FROM A FINANCIAL SERVICES BACKROUND NOT BP.
I COME FROM AN OUTSTANDING COMPANY THAT WAS TRANSPERNT AND ACCOUNTABLE.
WHERE IS THE EFFING DATA!
Your first premise is correct. WGT doesn't trust the FDA. The FDA has a long tradition of confusing symptoms with causes and since the dim-bulbs at the FDA are fully bought into the 'kill the plaque first to kill AD' thesis a drug that enhances autophagy but doesn't quickly melt plaque like butter on a hot skillet from non-big pharma is going to be treated with all the respect a hooker gets at 9 am Sunday mass.
The FDA has said a drug candidate for approval for AD will directly and primarily melt plaque. Cognition improvements are whooey to the FDA.
TGD had an approach based on Retts approval first. But then the placebo effect screwed up the pediatric retts readout.
Going to the FDA with cognition improvements is a waste of time.
Is a quiet period again! We seem to have had an endless contiguous stream of them.
Oh my! I’m guessing the pumpers aren’t being paid enough given how things are going.
Ziggy, here is what we know, but not everyone accepts these facts:
1) The officers and directors know the data, i.e., they can't buy shares during this "quiet period" (length unknown);
2) The EMA has seen a glimpse of the data and asked Anavex to file;
3) Rett results were 3x better than approved competitors' results and will be discussed with agencies, including fda; and,
4) New information on brain volume loss that shows Anavex's blarcamesine is less damaging, if at all, than the mabs' impact and this information might be added to filings in progress.
I believe Tred, Pazzo and ignatius have replied to directly and/or indirectly to some of the bashers over the weekend. The true situation at Anavex can't not be heard amongst all the cacophony around it.
We will know in time ... length unknown.
He shouldn't calm down. Anavex should be delivering. Maybe Palmer hasn't applied for FDA approval before, but Anavex has expensive experience in moving forward with the FDA on their payroll and should be doing what Palmer is asking. Anavex is way out of line here. They should be sued for neglecting shareholders...oh wait...
Really, I have basher recruitment agencies contacting me on a daily basis. I have been in multiple bidding wars in regards to amount per post. The going rate for Anavex is now $3 per negative post to keep up with inflation.
Honestly he wouldn’t need any more shares if he can exercise options on 6 million shares. It will be called greed if anyone buy more shares in that situation.
Missling has options on 6 million shares or so. So buying shares has little personal benefit.
So that leaves the "send a message" as the only reason for him to buy shares. Another word for that would be manipulation. Or as it was just described a cheap publicity stunt.
I suppose that might result in a short term SP bump. Whoopie.
Trial results are all that maters, the rest is entertainment.
Yes, look no further than SAVA whose director has bought big propping up the pps momentarily before it would drop some more. Why risk another possible batch of lawsuits from insider trading when you are close like we are.
Annnddd….I might add there is value in patience and navigating the prisms of the halls of the Fda. 1) data continues to pour out, like the brain shrinkage reduction. 2) the Fda is a changin, 3) every week/month another Alzh company fails or another mab gets disqualified by some governing agency in the world for reimbursement. A poker analogy would be that its kind of like sitting back and letting the chip bully take everyone else out as you wait for the best possible hand only in this case, we wont be second when we get done playing our hand.
Our drug will have the data to support mass adoption coupled with the safety and ability to reach patients globally in every walk of life! If Amazon can reach you, you are eligible! We have one shot, if we rush it and the Fda or EMA kick it back from a technicality causing a delay Dr Missling will get grief. If he takes his time to be thorough (German heritage shining through) he also gets grief. The latter though if done properly WILL be successful in achieving approval imo.
Cheers
You mean Misleading? Yep, that's absolutely correct
Nonsense. It doesn’t hurt, insider buying, but at most it’s a stunt that begets a brief and minor trading pop. Especially in the case of AVXL, which is being actively suppressed.
“WGT are really getting delusional”.
Delusions driven by fear and desperation. The reality is becoming harder and harder to deny.
Read these two articles about insider buying and its effect on market sentiment, then tell me insider buying makes no difference to the stock price:
https://www.emerald.com/insight/content/doi/10.1108/AJAR-09-2020-0089/full/html#sec005
https://www.investopedia.com/articles/02/121002.asp#:~:text=Stock%20prices%20rise%20more%20after,those%20of%20the%20overall%20market.
Here’s the bottom line: Insider buying matters.
Misleading released two sets of data for the same trial, and the stock plummeted because it turned out he had released post-hoc data. Until last month, he insisted the trial met all endpoints, but now he's claiming it only met one primary endpoint. Who would trust such a blatant liar?
NWBO followed the same playbook of releasing data in a journal two years after data lock (which was a joke). Nobody seems to care about peer review; after all, peer review is meant for research, not for FDA approval and commercialization.
WGT are really getting delusional.
If Anavex releases the data themselves, every nefarious actor will try and discredit the results. From the likes of known shorts to big pharma.
So why not let reputable scientists review and dissect the data, document their own thesis, and corroborate the data.
Stop being a whiny beatch and have some patience.
The peer-review article will be released when it’s ready.
plex, talk to george for b rain volume details if you aren't aware of them ... which, if you follow this Board, I don't know why you don't!.
Calm down, mrp ... all CAPS ... your BP might explode given your 50+ years of experience.
Have you filed for a drug approval ... and do you know what is involved? If so, please offer yourself as a Toutian replacement plus Director and show Anavex and TGD the way. I vote for you to get $800K annually with one million options at the year's lowest SP with 20 years to exercise! 😉
Please cite the person(s) blaming the fda. Most pro-Anavex don't trust the fda, given its past mabs' approvals on flimsy evidence and rejection of its adu* adcomm.
P.S. pogue, I don't believe you own any Anavex stock (9 years, BUNK!), other than as a negative ownership in a short position.
Those delusions of yours are cute. My disagreeing with immaterial FUD talking points indicates common sense, not some type of mindhold.
Followers
|
1065
|
Posters
|
|
Posts (Today)
|
55
|
Posts (Total)
|
460020
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |